Cargando…
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectivel...
Autores principales: | Mariz, Filipe Colaço, Bender, Noemi, Anantharaman, Devasena, Basu, Partha, Bhatla, Neerja, Pillai, Madhavan Radhakrisna, Prabhu, Priya R., Sankaranarayanan, Rengaswamy, Eriksson, Tiina, Pawlita, Michael, Prager, Kristina, Sehr, Peter, Waterboer, Tim, Müller, Martin, Lehtinen, Matti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021830/ https://www.ncbi.nlm.nih.gov/pubmed/32128255 http://dx.doi.org/10.1038/s41541-020-0165-x |
Ejemplares similares
-
Current global status & impact of human papillomavirus vaccination: Implications for India
por: Sankaranarayanan, Rengaswamy, et al.
Publicado: (2016) -
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
por: Joshi, Smita, et al.
Publicado: (2023) -
Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
por: Mariz, Filipe Colaco, et al.
Publicado: (2023) -
Building resilient cervical cancer prevention through gender-neutral HPV vaccination
por: Man, Irene, et al.
Publicado: (2023) -
Cancer of the cervix uteri: 2021 update
por: Bhatla, Neerja, et al.
Publicado: (2021)